[Bone diseases]

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

This is a brief review summarizing several topics in bone disease (study type and species not specified). It states calcium intake has a small impact on bone mineral density and fracture risk, that denosumab is a more potent inhibitor of bone resorption than zoledronate, that abaloparatide, a PTHrP analog, increases bone mineral density and decreases fracture incidence, and that teriparatide could potentially be delivered via a transdermic device. It also states romosozumab and odanacatib improve calculated bone strength, that sequential or combined denosumab and teriparatide treatment could be of interest but not denosumab followed by teriparatide, and that fibrous dysplasia, Paget disease, hypophosphatasia, atypical femoral fracture, and osteonecrosis of the jaw are covered as updated topics.